This does not imply that anticoagulation is to be started in asymptomatic aPL-positive patients with ANA, but that clinical and biological work-up should focus on microvascular features and/or cytopenias by, for example, assessing for silent APS nephropathy just as one would for lupus nephritis (31). This evidence concerns the gene FASLG and lupus nephritis.